<?xml version='1.0' encoding='utf-8'?>
<document id="24102384"><sentence text="Effects of erythromycin at steady-state concentrations on the pharmacokinetics of ulipristal acetate."><entity charOffset="11-23" id="DDI-PubMed.24102384.s1.e0" text="erythromycin" /><entity charOffset="82-100" id="DDI-PubMed.24102384.s1.e1" text="ulipristal acetate" /><pair ddi="false" e1="DDI-PubMed.24102384.s1.e0" e2="DDI-PubMed.24102384.s1.e0" /><pair ddi="false" e1="DDI-PubMed.24102384.s1.e0" e2="DDI-PubMed.24102384.s1.e1" /></sentence><sentence text="Ulipristal acetate (UPA) is a novel selective progesterone receptor modulator for the treatment of benign gynaecological conditions such as uterine myoma"><entity charOffset="0-18" id="DDI-PubMed.24102384.s2.e0" text="Ulipristal acetate" /><entity charOffset="20-23" id="DDI-PubMed.24102384.s2.e1" text="UPA" /><entity charOffset="46-58" id="DDI-PubMed.24102384.s2.e2" text="progesterone" /><pair ddi="false" e1="DDI-PubMed.24102384.s2.e0" e2="DDI-PubMed.24102384.s2.e0" /><pair ddi="false" e1="DDI-PubMed.24102384.s2.e0" e2="DDI-PubMed.24102384.s2.e1" /><pair ddi="false" e1="DDI-PubMed.24102384.s2.e0" e2="DDI-PubMed.24102384.s2.e2" /><pair ddi="false" e1="DDI-PubMed.24102384.s2.e1" e2="DDI-PubMed.24102384.s2.e1" /><pair ddi="false" e1="DDI-PubMed.24102384.s2.e1" e2="DDI-PubMed.24102384.s2.e2" /></sentence><sentence text=" In vitro, it is mainly metabolized by the cytochrome P450 isoenzyme CYP3A4 and to a small extent by CYP1A2 and CYP2D6" /><sentence text=" Erythromycin, a macrolide antibiotic, has been shown to be a moderate CYP3A4 inhibitor"><entity charOffset="1-13" id="DDI-PubMed.24102384.s4.e0" text="Erythromycin" /><entity charOffset="17-26" id="DDI-PubMed.24102384.s4.e1" text="macrolide" /><pair ddi="false" e1="DDI-PubMed.24102384.s4.e0" e2="DDI-PubMed.24102384.s4.e0" /><pair ddi="false" e1="DDI-PubMed.24102384.s4.e0" e2="DDI-PubMed.24102384.s4.e1" /></sentence><sentence text=" Thus, the aim of this study was to determine the effects of erythromycin at steady-state concentrations on the pharmacokinetics of UPA"><entity charOffset="61-73" id="DDI-PubMed.24102384.s5.e0" text="erythromycin" /><entity charOffset="132-143" id="DDI-PubMed.24102384.s5.e1" text="UPA" /><pair ddi="false" e1="DDI-PubMed.24102384.s5.e0" e2="DDI-PubMed.24102384.s5.e0" /><pair ddi="false" e1="DDI-PubMed.24102384.s5.e0" e2="DDI-PubMed.24102384.s5.e1" /></sentence><sentence text=" Effects on the pharmacokinetics of the mono-demethylated metabolite of UPA (PGL4002) were also evaluated"><entity charOffset="72-74" id="DDI-PubMed.24102384.s6.e0" text="UPA" /></sentence><sentence text="" /><sentence text="This was a non-randomized, single-sequence, two-period, open, single-dose study in 18 healthy female subjects" /><sentence text=" Subjects received oral UPA (20 mg) once daily on days 1 and 13 and twice-daily erythromycin propionate administrations (500 mg) from days 9 through 17"><entity charOffset="80-103" id="DDI-PubMed.24102384.s9.e0" text="erythromycin propionate" /><entity charOffset="24-46" id="DDI-PubMed.24102384.s9.e1" text="UPA" /><pair ddi="false" e1="DDI-PubMed.24102384.s9.e1" e2="DDI-PubMed.24102384.s9.e1" /><pair ddi="false" e1="DDI-PubMed.24102384.s9.e1" e2="DDI-PubMed.24102384.s9.e0" /></sentence><sentence text="" /><sentence text="Geometric mean Cmax and AUCs of UPA were increased by 24% [geometric mean ratio point estimate (90% CI): 1·24 (1·01-1·52)] and +224% and +227% [geometric mean ratio point estimates (90% CI): AUC0-t 3·24 (2·75-3·83) and AUC0-∞ (3·27 (2·79-3·83)], respectively, with no effect on median tmax or t1/2"><entity charOffset="219-225" id="DDI-PubMed.24102384.s11.e0" text="AUC0-∞" /><entity charOffset="32-37" id="DDI-PubMed.24102384.s11.e1" text="UPA" /><pair ddi="false" e1="DDI-PubMed.24102384.s11.e1" e2="DDI-PubMed.24102384.s11.e1" /><pair ddi="false" e1="DDI-PubMed.24102384.s11.e1" e2="DDI-PubMed.24102384.s11.e0" /></sentence><sentence text=" Geometric mean Cmax of PGL4002 was decreased by 47% [geometric mean ratio point estimate (90% CI): 0·523 (0·44-0·62)], but AUCs were increased by +62% and +66% [geometric mean ratio point estimates (90% CI): AUC0-t 1·62 (1·43-1·85) and AUC0-∞ by 1·66 (1·47-1·88)], respectively, with no effect on median tmax" /><sentence text=" However, geometric mean t1/2" /><sentence text="doubled from 24 h to 48 h" /><sentence text=" No subject was discontinued from the study due to adverse events" /><sentence text="" /><sentence text="Concomitant use of ulipristal acetate with erythromycin at therapeutic concentrations led to a limited increase in Cmax and a 3-fold increase in AUCs for UPA and to a decrease in Cmax and an increase in AUCs and prolonged elimination for PGL4002"><entity charOffset="19-37" id="DDI-PubMed.24102384.s17.e0" text="ulipristal acetate" /><entity charOffset="43-55" id="DDI-PubMed.24102384.s17.e1" text="erythromycin" /><entity charOffset="154-165" id="DDI-PubMed.24102384.s17.e2" text="UPA" /><pair ddi="false" e1="DDI-PubMed.24102384.s17.e0" e2="DDI-PubMed.24102384.s17.e0" /><pair ddi="false" e1="DDI-PubMed.24102384.s17.e0" e2="DDI-PubMed.24102384.s17.e1" /><pair ddi="false" e1="DDI-PubMed.24102384.s17.e0" e2="DDI-PubMed.24102384.s17.e2" /><pair ddi="false" e1="DDI-PubMed.24102384.s17.e1" e2="DDI-PubMed.24102384.s17.e1" /><pair ddi="false" e1="DDI-PubMed.24102384.s17.e1" e2="DDI-PubMed.24102384.s17.e2" /></sentence><sentence text=" This indicates that inhibition of CYP3A4 impacted rate and extent of absorption of UPA and also its metabolism by slowing the elimination of its metabolite PGL4002"><entity charOffset="84-86" id="DDI-PubMed.24102384.s18.e0" text="UPA" /></sentence><sentence text="" /></document>